SCHEMBL6491045

SCHEMBL6491045

CCOc1ccc(Cn2c(C)nc3c(C)cc(-c4ccc(C(=O)OC)cn4)cc32)c(Cl)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
DCTPP1 Q9H773 3/20 0.42
KDM4E B2RXH2 1/20 0.37
CHRNA7 P36544 1/20 0.36
BRD4 O60885 1/20 0.36
PPARG P37231 1/20 0.36
TSPO P30536 1/20 0.35
TLR7 Q9NYK1 1/20 0.35
F2RL3 Q96RI0 1/20 0.34
MAPT P10636 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
DRD2 P14416 1/20 0.34
TBXA2R P21731 1/20 0.34
MEN1 O00255 1/20 0.34
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
CNR2 P34972 1/20 0.34
BUB1 O43683 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488103 0.92 P4HTM (0.40) DCTPP1CHRNA7PPARGTSPOMAPT
SCHEMBL6489130 0.84 MAPT (0.40) DCTPP1CHRNA7PPARGTSPOMAPT
SCHEMBL6488456 0.83 DCTPP1 (0.44) DCTPP1CHRNA7PPARGTSPO
SCHEMBL6487673 0.83 JMJD6 (0.41) DCTPP1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6501593 0.82 KDM4C (0.44) DCTPP1
SCHEMBL6490742 0.81 CYP1A2 (0.38) DCTPP1KDM4ETSPOMAPTSMN1; SMN2
SCHEMBL6488896 0.81 DCTPP1 (0.40) DCTPP1KDM4EPPARGMAPTSMN1; SMN2
SCHEMBL6502432 0.80 PPARG (0.42) DCTPP1PPARGSMN1; SMN2MEN1KMT2A
SCHEMBL6489353 0.80 PIK3C2B (0.38) DCTPP1TSPOMAPTSMN1; SMN2
SCHEMBL6490528 0.80 DCTPP1 (0.42) DCTPP1PPARGSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050014812-A1 Benzimidazole compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-01-20 US disclosed
WO-2004108686-A2 BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014812-A1 Benzimidazole compounds SLC5A1, SLC5A2, G6PD DCTPP1 1534/4885KDM4E 760/4885CHRNA7 4375/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.